within Pharmacolibrary.Drugs.ATC.C;

model C09AA16
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.42,
    Cl             = 18 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005833333333333333,
    Tlag           = 12.0
  );

  annotation(Documentation(
    info ="<html><body><p>Imidapril is an angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and heart failure. It acts as a prodrug, converting to its active metabolite imidaprilat after oral administration. Imidapril is approved for clinical use in several countries but is not available in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Yun, JH, et al., &amp; Hwang, SJ (2005). LC-MS determination and bioavailability study of imidapril hydrochloride after the oral administration of imidapril tablets in human volunteers. <i>Archives of pharmacal research</i> 28(4) 463–468. DOI:<a href=&quot;https://doi.org/10.1007/BF02977677&quot;>10.1007/BF02977677</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15918521/&quot;>https://pubmed.ncbi.nlm.nih.gov/15918521</a></p></li><li><p>Hosoya, K, &amp; Ishimitsu, T (2002). Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. <i>Cardiovascular drug reviews</i> 20(2) 93–110. DOI:<a href=&quot;https://doi.org/10.1111/j.1527-3466.2002.tb00185.x&quot;>10.1111/j.1527-3466.2002.tb00185.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12177688/&quot;>https://pubmed.ncbi.nlm.nih.gov/12177688</a></p></li><li><p>Harder, S, &amp; Thürmann, PA (1997). Pharmacokinetic and pharmacodynamic interaction trial after repeated oral doses of imidapril and digoxin in healthy volunteers. <i>British journal of clinical pharmacology</i> 43(5) 475–480. DOI:<a href=&quot;https://doi.org/10.1046/j.1365-2125.1997.00588.x&quot;>10.1046/j.1365-2125.1997.00588.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9159562/&quot;>https://pubmed.ncbi.nlm.nih.gov/9159562</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C09AA16;
